Mass Spectrometry Software Market reach US$ 8,541.36 million by 2027

The mass spectrometry software market was valued at US$ 5,037.56 million in 2019 and is projected to reach US$ 8,541.36 million by 2027; it is expected to grow at a CAGR of 7.0% from 2020 to 2027.

The scope of the mass spectrometry software market includes deployment type, application, and region. The market for mass spectrometry software is analyzed based on regions such as North America, Europe, Asia Pacific, Middle East & Africa, and South and Central America. The report offers insights and in-depth analysis of the mass spectrometry software market emphasizing on various parameters, such as market trends, technological advancements, market dynamics, and competitive landscape analysis of leading market players across the world.

Download Sample Copy @ https://www.theinsightpartners.com/sample/TIPRE00016153/?utm_source=OpenPR&utm_medium=10379

Company Profiles
Waters Corporation
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
Sciex (Danaher Corporation)
Advanced Chemistry Development
Bruker
Adaptas Solutions
SpectralWorks Ltd.
Shimadzu Scientific Instruments
PerkinElmer, Inc.

Market Insights
Increasing Applications of Genomics and Proteomics
Growing advancements in technology have enhanced the genomic and proteomic applications in the biotechnology industry. These applications are majorly dependent on mass spectrometry-based identification and quantification outcomes. The integration of information technology with biotechnology has allowed receiving genome-sequence databases automatically by rapid protein profiling. It offers benefits such as real-time analysis of continuously flowing protein samples that can be used for medical applications.

Growing applications of genomics and proteomics in the medical industry for diagnosing and treating chronic diseases have increased the utilization of mass spectroscopy. Mass spectrometry has enabled the invention of therapeutic techniques to design personalized treatments for diseases, such as cancer, diabetes, and genetic disorders. Various innovations have received support from government organizations worldwide to enhance the research and development in the biotechnology industry. For instance, in 2006, the National Cancer Institute and National Human Genome Research Institute collaborated to lead significant initiatives-such as Cancer Genome Atlas-for the development of personalized medicines for oncology. Under the program, ~47 drugs have been approved by the Food and Drug Administration in 2018, and nearly 20 by the mid of 2019.

By Deployment Type
Cloud-based
On-premises
 
By Application
Pharmaceutical Companies
Research Organizations and Institutions
Others

Get a Full Copy of This Report @ https://www.theinsightpartners.com/buy/TIPRE00016153/?utm_source=OpenPR&utm_medium=10379

Contact US
Contact Person : Sameer Joshi
Phone : +1-646-491-9876
E-mail : sales@theinsightpartners.com

About US
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.

This release was published on openPR.